Melissa de los Reyes

机构：AstraZeneca (Australia), AstraZeneca (Canada) · ORCID：0000-0002-6055-0413

发表论文 107 篇 · 总被引 1378 次 · h-index 13

代表论文

• Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis (2023 · Arthritis & Rheumatology · 被引 20)
• Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes (2025 · Clinical Cancer Research · 被引 4)
• Data from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2023 · 被引 1)
• Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis (2026 · Arthritis & Rheumatology)
• Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2025)
• Figure S1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2025)